| Abstract | Farmaceutska industrija ubraja se u najprofitabilnije industrije čija vrijednost raste i u vrijeme globalne financijske krize. Jedna od glavnih karakteristika i sve veći trend u farmaceutskoj industriji su učestala preuzimanja poduzeća. Istek patenata na blockbuster lijekove, širenje proizvodnog portfelja i nadoknađivanje manjka vlastitih proizvoda u razvoju su temeljni razlozi zbog kojih dolazi do preuzimanja unutar farmaceutske industrije. Danas se farmaceutske kompanije sve teže odlučuju na ulaganja u istraživanje i razvoj zbog velike rizičnosti i male vjerojatnosti uspjeha proizvoda zbog čega, umjesto da same razvijaju proizvod, sve više ulažu u procese preuzimanja poduzeća koja imaju obećavajuće razvojne proizvode.
Nakon višemjesečnog nadmetanja sa islandskim Actavisom, najveću hrvatsku farmaceutsku kompaniju Plivu je 2006. godine preuzeo američki proizvođač generičkih lijekova Barr Pharmaceuticals. Glavni cilj te integracije je ekspanzija poduzeća na nova tržišta odnosno ekspanzija Barra na tržište Europe te Plive na američko tržište. Ubrzo zatim, 2008. godine, Teva je preuzela kompaniju Barr Pharmaceuticals čime je Pliva postala dio Teva grupe. Teva je vodeći svjetski proizvođač generičkih lijekova koji godišnje proizvede oko 73 milijarde lijekova. Cilj ove integracije je bio ojačati Tevinu vodeću poziciju na američkom tržištu generičkih lijekova kao i poziciju na ključnim tržištima u Europi.
Teva znatno ulaže u Plivin segment istraživanja i razvoja koji je temelj za razvoj novih lijekova. Osim toga, ulaže i u proizvodne pogone što rezultira povećanom proizvodnjom i izvozom. U Zagrebu je otvorila najveći centar za ljudske potencijale u Europi, a uskoro slijedi otvorenje uslužnog centra za nabavne aktivnosti. Osim zapošljavanja, Tevine investicije donose i pozitivan imidž Hrvatskoj. |
| Abstract (english) | The pharmaceutical sector is one of the most profitable industries, the value of which has been growing even in the period of the global financial crisis. One of the primary characteristics and a trend on the rise in the pharmaceutical industry is the increase in the number of acquisitions. Blockbuster drug patent exploration, widening the manufacturing portfolio and compensating for not developing their own products are among the chief reasons why so many acquisitions in the pharmaceutical industry have been taking place. Today, major pharmaceutical companies are hesitant to invest into research and development due to high risk factors and small probability of product success, due to which, instead of developing products themselves, they opt for investment in the form of acquiring business with promising products under development.
In 2006, after several months of competing with the Icelandic Actavis, the largest Croatian pharmaceutical company Pliva was acquired by the US producer of generic pharmaceuticals Barr Pharmaceuticals. The primary objective of said integration was the company’s expansion onto new markets, i.e. Barr’s expansion into Europe and Pliva’s to the US market. Soon after, in 2008, Teva acquired Barr Pharmaceuticals, making Pliva integral part of Teva Group. Teva is a leading global producer of generic pharmaceuticals, with annual output of 73 billion medicines. The objective of this integration was to strengthen Teva’s leading position on the US generic pharmaceuticals’ market, as well as its position on key European markets.
Teva has been investing heavily into Pliva’s research and development segment, which provides the foundation for the development of new pharmaceuticals. Furthermore, it has been investing into production plants, resulting in increased production and export. Zagreb has also become the biggest Centre for Human Resources in Europe, and the Procurement Service Centre is to be launched soon. Apart from employment possibilities, Teva’s investments have had a positive influence regarding Croatia’s image. |
